Percutaneous implantation of a 26 mm Edwards SAPIEN-XT aortic valve prosthesis in a degenerated 30 mm mitral annuloplasty ring
نویسندگان
چکیده
منابع مشابه
Percutaneous implantation of a 26 mm Edwards SAPIEN-XT aortic valve prosthesis in a degenerated 30 mm mitral annuloplasty ring.
della Carità, Novara: G. De Luca, E. Franchi, M. Leverone, A. Rognoni. Clinical events committee: Chairman: Prof. Sandra Brunelleschi PhD. Istituite of Clinical Pharmacology, School of Medicine of the Università del Piemonte Orientale, Novara. Mauro Feola MD, Division of Cardiology, Ospedale S. Trinità, Fossano. Giuliana Menegatti MD, Division of Cardiology, Ospedale Civile Maggiore di Verona. ...
متن کاملTransfemoral tricuspid valve-in-ring implantation using the edwards Sapien XT valve: one-year follow-up.
after multidisciplinary evaluation, 3 high-risk patients underwent transfemoral tricuspid valve-in-ring implantation (TVIRI) for refractory congestive heart failure because of deterioration of their tricuspid surgery, using Sapien XT valves (Edwards Lifesciences Inc, Irvine, CA). Patient 1: 44-year-old man, drug abuse, 4 episodes of tricus-pid endocarditis, 2 previous cardiac surgeries for mitr...
متن کاملSuccessful Transfemoral Edwards Sapien Aortic Valve Implantation in a Patient with Previous Mitral Valve Replacement
Transcatheter aortic valve implantation (TAVI) is a new method for patients with severe aortic stenosis at high surgical risk, such as previous cardiac surgery. The presence of mechanical mitral prosthesis might complicate TAVI because of possible interference between the both prosthesis. Some reports have already demonstrated the feasibility of TAVI in such patients. We report our experience w...
متن کاملTransfemoral aortic valve replacement with the Edwards SAPIEN and Edwards SAPIEN XT prosthesis using exclusively local anesthesia and fluoroscopic guidance: feasibility and 30-day outcomes.
OBJECTIVES The authors report the feasibility and 30-day outcomes of transfemoral aortic valve replacement (TAVR), using the Edwards SAPIEN (Edwards Lifesciences, Irvine, California) and Edwards SAPIEN XT (Edwards Lifesciences) prosthesis, implanted using exclusively local anesthesia and fluoroscopic guidance. BACKGROUND Transfemoral TAVR is often managed with general anesthesia. However, a s...
متن کاملEmergency transapical mitral valve-in-valve implantation for bioprosthesis failure: transapical implantation of an Edwards Sapien-XT in a dysfunctional mitral bioprosthesis in a critical patient
Background: Valve-in-Valve (VIV) Transcatheter Aortic Valve Replacement (TAVR) is now the treatment of choice in high-surgical-risk patients with failing aortic bioprosthesis. Although less performed, VIV-Transcatheter Mitral Valve Replacement (TMVR) is a valid treatment option for selected high-risk patients with degenerated mitral bioprostheses. Several cases of elective ViVTAVR and -TMVR hav...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2013
ISSN: 1522-9645,0195-668X
DOI: 10.1093/eurheartj/eht119